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Green tea inhibited the elimination 
of nephro-cardiovascular toxins 
and deteriorated the renal function 
in rats with renal failure
Yu-Hsuan Peng1, Douglas H. Sweet2, Shiuan-Pey Lin1, Chung-Ping Yu1, Pei-Dawn Lee Chao1 
& Yu-Chi Hou1,3,4
Chronic kidney disease (CKD) is a major health problem worldwide. Indoxyl sulfate (IS) and p-cresyl 
sulfate (PCS) are highly protein-bound nephro-cardiovascular toxins, which are not efficiently 
removed through hemodialysis. The renal excretions of IS and PCS were mediated by organic 
anion transporters (OATs) such as OAT1 and OAT3. Green tea (GT) is a popular beverage containing 
plenty of catechins. Previous pharmacokinetic studies of teas have shown that the major molecules 
present in the bloodstream are the glucuronides/sulfates of tea catechins, which are putative 
substrates of OATs. Here we demonstrated that GT ingestion significantly elevated the systemic 
exposures of endogenous IS and PCS in rats with chronic renal failure (CRF). More importantly, GT 
also significantly increased the levels of serum creatinine (Cr) and blood urea nitrogen (BUN) in CRF 
rats. Mechanism studies indicated that the serum metabolites of GT (GTM) inhibited the uptake 
transporting functions of OAT1 and OAT3. In conclusion, GT inhibited the elimination of nephro-
cardiovascular toxins such as IS and PCS, and deteriorated the renal function in CRF rats.
Chronic kidney disease (CKD) is affecting the health of more and more people worldwide1. The main 
feature at the end stage of CKD is the accumulation of endogenous uremic toxins2,3, among which 
indoxyl sulfate (IS) and p-cresyl sulfate (PCS) are highly protein-bound and cannot be efficiently removed 
through hemodialysis4. Moreover, the elevated serum levels of IS and PCS were associated with the pro-
gression of CKD and cardiovascular diseases (CVD) as well as all-cause mortality5–7. Owing to the acidic 
properties, IS and PCS are existing as anions under physiological pH in the systemic circulation, and the 
uptake transports of IS and PCS across the cell membranes of renal proximal tubules were mediated by 
organic anion transporters (OATs) such as OAT1 and OAT38–10.
Habitual consumption of teas, leaves and buds of Cammellia sinensis, has long been considered to 
have many health benefits such as prevention of CVD and cancers11,12. Green tea (GT) is one of the most 
popular teas containing plenty of catechins such as (− )-epicatechin (EC), (− )-epigallocatechin (EGC), 
(− )-epicatechin-3-gallate (ECG) and (− )-epigallocatechin-3-gallate (EGCG), which account for up to 
30% of the dry leaf weight13. Previous studies on tea catechin pharmacokinetics have reported that EC 
glucuronides/sulfates and EGC glucuronides/sulfates were the major molecules in the bloodstream14–16. 
Given the anionic nature of glucuronides/sulfates under physiological pH, these conjugated metabolites 
of tea catechins are putative substrates of OATs17. We therefore hypothesized that the serum metabolites 
of GT (GTM) might inhibit the uptake transport of IS and PCS across the cell membrane of renal prox-
imal tubule mediated by OAT1 and OAT3, which in turn would lead to elevated blood levels of IS and 
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PCS in CKD patients with lower expressions of OATs18,19, and consequently promote the progression of 
CKD and CVD.
Although GT has been found to show renal and cardiovascular protective effects in healthy sub-
jects20–22, till now whether GT likely benefits CKD patients remains unknown. Previous studies have 
reported that adenine-induced chronic renal failure (CRF) rats showed lower protein expressions of 
OAT1 and OAT3 along with the decreased clearance of IS and PCS19,23. Hence, a CRF rat model induced 
with adenine was adopted in this study to investigate the effect of GT on the serum levels of endog-
enous IS and PCS. Moreover, the effect of GT on the renal function of CRF rats was also evaluated. 
Furthermore, cell models were used to verify the involvement of OAT1 and OAT3 in the mechanism.
Results
Quantitation of tea catechins in GT infusion. GT infusion was analyzed by LC-MS/MS and the 
chromatograms were shown in Fig.  1. The quantitation results showed that the concentrations of EC, 
EGC, ECG and EGCG were 966.7, 919.9, 739.7 and 1960.1 μ g/mL (3.33, 3.17, 2.55 and 6.75 mM), respec-
tively, in the GT infusion.
Characterization of the serum metabolites of GT (GTM). For mimicking the molecules interact-
ing with OAT1 and OAT3 located on the membrane of renal proximal tubular cells, GTM was prepared 
from rats after receiving GT infusion. Characterization of GTM indicated that the concentrations of the 
free forms of EC, EGC, ECG and EGCG were 0.86, 2.17, 0.06 and 0.13 μ M, respectively. After hydrolysis 
with sulfatase/glucuronidase, the peaks of EC, EGC, ECG and EGCG were all enhanced, in particular 
EC and EGC as shown in Fig. 2. The concentrations of free form and the sulfates/glucuronides of each 
tea catechin in GTM are listed in Table 1, showing that the major molecules in GTM were the sulfates/
glucuronides of EC and EGC. The concentrations of the sulfates/glucuronides of EC, EGC, ECG and 
EGCG were 32.47, 33.29, 0.13 and 0.40 μ M, respectively, which have been obtained by subtracting the 
free form concentrations from those after hydrolysis.
Quantitation of IS and PCS in serum. The analytical methods of IS and PCS were established and 
validated in this study. Good linear relationships existed in the concentration ranges of 0.4–25.0 μ g/mL 
(Y = 0.246 X + 0.006, r = 0.9999) for IS and 0.3–20.0 μ g/mL (Y = 0.045 X + 0.010, r = 0.9996) for PCS 
in serum. Validation of the analytical methods for IS indicated that the coefficients of variation (CVs) 
of intraday and interday analysis were below 6.4% and 7.6%, and the relative errors (R.E.) were below 
12.1% and 9.9%, respectively. The CVs of PCS of intraday and interday analysis were below 17.0% and 
12.6%, and the R.E. were below 10.9% and 7.8%. The recoveries of IS at 0.8, 3.1 and 12.5 μ g/mL from 
serum were 88, 101 and 100%, and those of PCS at 0.6, 2.5 and 10.0 μ g/mL were 104, 103 and 105%. The 
LLOQ of IS and PCS were 0.4 and 0.3 μ g/mL, and LOD were 0.01 and 0.04 μ g/mL.
Establishment of CRF model and effect of GT on the serum levels of IS and PCS in CRF 
rats. The dosing times of adenine and GT as well as scheduled time of blood collection are summa-
rized in Fig.  3. After administration of five consecutive doses of adenine, the mean serum IS level in 
28 rats was significantly elevated from 6.85 to 15.35 μ M (P < 0.001), and PCS level was increased from 
5.59 to 7.49 μ M (P = 0.14) on day 4 as shown in Fig. 4. The serum profiles of endogenous IS and PCS 
in CRF rats following oral administration of GT at 200 and 400 mg/kg are shown in Fig. 5. The profiles 
clearly showed that ingestion of GT dose-dependently increased the serum levels of IS and PCS. The 
Figure 1. LC-MS/MS chromatograms of EC (1), EGC (2), ECG (3), EGCG (4) and 6,7-DMC (5, internal 
standard) in GT infusion. 
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pharmacokinetic parameters of IS and PCS are listed in Table  2. The results showed that ingestion of 
400 mg/kg of GT significantly increased the AUC0-360 of IS and PCS by 139.2% and 118.4%, respectively, 
and elevated Cmax of IS by 123.3%, whereas the Cmax of PCS was not affected. In contrast, when GT was 
given at a lower dose of 200 mg/kg, the profiles of IS and PCS were higher than the control curves, how-
ever, the differences of Cmax and AUC0-360 did not reach statistical significance.
Effect of GT on the renal function of CRF rats. After administration of five consecutive doses 
of adenine, the mean Cr of 14 rats was significantly elevated from 0.30 to 0.58 mg/dL, and BUN was 
increased from 21.0 to 60.1 mg/dL on day 4. The concentrations of Cr and BUN in CRF rats after giving 
the 7th dose of GT and water are shown in Table 3. The mean Cr and BUN in GT group were 0.79 and 
55.1 mg/dL, respectively, which were significantly higher than those in water group (0.49 and 40.9 mg/
dL).
Effects of GTM on the uptake transport mediated by hOAT1 and hOAT3. The effects of GTM 
on the uptake activity of hOAT1 and hOAT3 are shown in Fig. 6. GTM at 1/4− , 1/2− and 1-fold serum 
concentrations significantly reduced the intracellular accumulation of 6-CF, an OAT1 substrate, by 43.9, 
Figure 2. LC-MS/MS chromatograms of EC (1), EGC (2), ECG (3), EGCG (4) and 6,7-DMC (5, internal 
standard) in serum before (left) and after treatment with glucuronidase/sulfatase (right). 
Catechins EC EGC ECG EGCG
free form 0.86 2.17 0.06 0.13
S/G 32.47 33.29 0.13 0.40
Table 1.  Concentration (μM) of free form and the sulfates/glucuronides (S/G) of tea catechins in GTM.
Figure 3. Scheduled time of blood collection (▲) and dosing time of adenine and GT (↑). 
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41.9 and 58.1%, respectively, when compared with blank serum specimen at corresponding concentra-
tions. Likewise, GTM at 1/2− and 1-fold serum concentration significantly reduced the intracellular 
accumulation of 5-CF, an OAT3 substrate, by 36.4% and 31.3%, respectively, when compared to blank 
serum specimen at corresponding concentration. As positive control inhibitors of hOAT1 and hOAT3, 
probenecid (80 μ M) significantly reduced the intracellular accumulation of 6-CF and 5-CF by 50.4 and 
50.7%, respectively. These in vitro studies indicated that GTM significantly inhibited the uptake transport 
mediated by hOAT1 and hOAT3.
Figure 4. Mean (±S.E.) serum IS (left) and PCS (right) concentrations in 28 rats before and after 
administration of seven doses of adenine (15 mg/rat). ***P < 0.001.
Figure 5. Mean (±S.E.) serum concentration - time profiles of endogenous IS (left) and PCS (right) 
after administration of the 7th dose of 400 mg/kg of GT (•, n = 10), 200 mg/kg of GT (▽, n = 8) and 
water (○, n = 10) in CRF rats. 
Treatments
IS PCS
Cmax AUC 0-360 Cmax AUC 0-360
Water 12.5 ± 1.4a 2957.8 ± 434.4a 7.8 ± 1.6 1767.4 ± 350.2a
GT 200 mg/kg 17.1 ± 1.4a 3747.4 ± 421.9a 10.1 ± 2.2 2737.3 ± 589.2a,b
GT 400  mg/kg 28.0 ± 2.7b 7074.7 ± 776.7b 10.0 ± 3.2 3859.3 ± 659.82 b
(+123.3%) (+139.2%) (+118.4%)
Table 2.  Effect of GT on Cmax and AUC 0-360 of IS and PCS in CRF rats. a,bSignificant difference at 
P < 0.05 between means are denoted by different superscripts. Data expressed as mean ± S.E. Cmax (μ M): 
maximum plasma concentration. AUC 0-360 (μ mol·min/L): the area under concentration-time curve from 0 
to 360 min.
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Discussion
Quantitation results revealed that EGCG was the major tea catechin in GT infusion, whereas the major 
molecules in GTM were the sulfates/glucuronides of EC and EGC. These finding largely resonated with 
the results reported previously16. Based on these facts, we could infer that ECG and EGCG were feasi-
bly hydrolyzed by esterase to form EC and EGC, respectively, which were then extensively metabolized 
by conjugation reactions to yield EC sulfates/glucuronides and EGC sulfates/glucuronides as the major 
molecules circulating in the bloodstream.
In regard to the quantitation of IS and PCS in serum, two HPLC methods using different internal 
standard and detection wavelengths have been developed and optimized in this study owing to the dis-
crepant physicochemical properties between IS and PCS. Validation of the analytical methods confirmed 
that the precision, accuracy and recovery were satisfactory for the quantitation of IS and PCS in serum.
In clinical setting, CKD patients are often exposed to increased blood levels of endogenous uremic 
toxins such as IS and PCS, which are by-products of protein metabolism24,25. A recent study reported 
that the serum concentrations of IS and PCS in healthy subjects were 1.03 and 13.03 μ M26. In contrast, 
for non-hemodialyzed stage 3–5 CKD patients the serum concentrations of IS and PCS were 17.45 and 
73.47 μ M, while in those CKD patients undergoing treatment with hemodialysis (stage 5D), they were 
81.04 and 120.54 μ M26. This highlights the fact that IS and PCS are highly protein bound (89% and 96%) 
and thus not efficiently removed through hemodialysis27–30. In regard to the relative abundance of IS and 
PCS in blood, the IS level was found consistently higher than PCS level in rats31–33, which appears oppo-
site to that in humans. This discrepancy between rats and humans might stem from species difference 
in protein metabolism23,27,34.
In order to mimic the biological condition of CKD with lower expression of OATs, adenine was used 
to induce CRF in this study19,23,35,36. The serum levels of IS and PCS in our CRF rats had been elevated 
to 15.4 and 7.6 μ M, which were largely close to those values in previous studies31–33. On other hand, 
the levels of serum Cr and BUN were significantly elevated, indicating that the renal function of rats 
was impaired by adenine36,37. After giving seven doses of GT to the CRF rats, the higher dose of GT 
at 400 mg/kg significantly increased the systemic exposures of IS and PCS, whereas the lower dose at 
200 mg/kg did not result in significant increases, indicating that large quantity of GT inhibited the elimi-
nation of IS and PCS. Moreover, the levels of serum Cr and BUN were significantly increased by 400 mg/
kg of GT, indicating that GT deteriorated the renal function of CRF rats, which might be accounted for 
by the increased systemic exposure of uremic toxins such as IS and PCS.
The uptake transports of IS and PCS across cell membrane were well known to be mediated by OAT1 
and OAT38,9. In regard to the magnitudes of influences, it was apparent that the effect of GT on the 
Cr BUN
Treatments Water GT Water GT
Day 0 0.30 ± 0.0 0.30 ± 0.0 21.1 ± 0.9 20.9 ± 1.2
Day 4 0.59 ± 0.0 0.57 ± 0.0 67.0 ± 6.3 53.1 ± 2.2
Day 8 0.49 ± 0.0 0.79 ± 0.1* 40.9 ± 3.3 55.1 ± 5.7**
Table 3.  Effect of GT on Cr and BUN (mg/dL) in 14 rats (7 rats/group). *P < 0.05 compared to water 
group. Day 0: before adenine treatment. Day 4: before GT dosing. Day 8: after 7th dose of GT and water. 
Data expressed as mean ± S.E.
Figure 6. Effects of GTM (1, 1/2 and 1/4 -fold serum concentrations) and probenecid (Prob, 80 μM) on 
the intracellular accumulation of 6-CF in CHO-hOAT1 cells (left) and 5-CF in HEK293-hOAT3 cells 
(right). *P < 0.05, **P < 0.01 and ***P < 0.001.
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serum levels of IS was in a greater extent than PCS. It has been reported that the uptakes of IS by OAT1 
and OAT3 were saturable with Km values of 21 μ M and 263 μ M, respectively38. Regarding PCS, the Km 
for the OAT1-mediated uptake was 128 μ M, whereas saturation was not observed for OAT3-mediated 
transport up to 5 mM39. Given the lower Km values of IS than PCS in both OAT1- and OAT3- mediated 
uptake, IS should be a substrate for OAT1 and OAT3 with lower capacity. Therefore, the uptake trans-
ports of IS mediated by OAT1 and OAT3, especially OAT1, were more easily to be saturated than those 
of PCS, which can account for the fact that GT elevated the serum levels of IS more than PCS.
In order to explore the mechanisms involved, GTM was prepared for mimicking the molecules inter-
acting with renal OAT1 and OAT340,41. Characterization of GTM demonstrated that the major molecules 
in the serum were EC glucuronides/sulfates and EGC glucuronides/sulfates, which echoed the finding in 
precedent studies14,16. Cell line studies showing that GTM exhibited inhibition on the uptake transport 
mediated by OAT1 and OAT3 could explain the increased serum levels of IS and PCS caused by GT. We 
speculated that these mechanisms associated with OAT1 and OAT3 in CRF rats could be extrapolated 
to CKD patients, because the distribution and function of OATs in rat kidney are similar to those in 
humans42–44.
Despite various health benefits of tea consumption to healthy humans20–22, the present study demon-
strated that GT inhibited the elimination of nepro-vascular toxins such as IS and PCS, and deteriorated 
the renal function in CRF rats. Considering that high blood levels of IS and PCS increased oxidative 
stress, inflammatory mediators and chemokines in the body45, we suspect consuming large quantity of 
GT might result in promoting the progression of CKD and CVD in CKD patients. Moreover, owing to 
the inefficient removal of IS and PCS through hemodialysis, GT consumption might also exacerbate 
the pathologies of CKD and CVD in end-stage CKD patients even under hemodialysis treatment5–7. 
Therefore, we suggest that CKD patients should avoid drinking large quantity of tea beverages before 
benefits or risks to CKD patients assessed by future clinical studies. In conclusion, GT inhibited the 
elimination of nephro-cardiovascular toxins such as IS and PCS through inhibition on OAT1 and OAT3, 
and deteriorated the renal function in CRF rats.
Materials and Methods
Chemicals and reagents. GT was purchased from the market in Taichung, Taiwan. IS (purity 97%) 
was obtained from Alfa Aesar (Lancaster, UK). 6,7-dimethoxycoumarin (6,7-DMC, purity 98%) was 
supplied by Aldrich Chemical Co. (Milwaukee, WI, U.S.A.). EC (purity 90%), ECG (purity 98%), EGCG 
(purity 95%), formic acid, probenecid, phosphoric acid (glacial, 85%) and methyl-paraben were purchased 
from Sigma Chemical Co. (St. Louis, MO, U.S.A.). EGC (purity 92.7%) was obtained from ChromaDex, 
Inc. (Irvine, CA, U.S.A.). and ethyl acetate were LC grade and obtained from ECHO Chemical Co. 
(Miaoli Hsien, Taiwan). Acetonitrile was LC/MS grade and was purchased from Millinckrodt Baker, Inc. 
(Phillipsburg, NJ, U.S.A.). Fetal bovine serum was obtained from Biological Industries Inc. (Kibbutz, 
Beit Haemek, Israel). Penicillin-Streptomycin-Glutamine, Dulbecco’ s Modified Eagle Medium, trypsin/
EDTA, Hank’s Balanced Salt Solution and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid were pur-
chased from Invitrogen (Carlsbad, CA, U.S.A.). Dulbecco’s Modified Eagle Medium F12 was obtained 
from Thermo Fisher Scientific Inc (Waltham, MA, U.S.A.). 6-Carboxyfluorescein was purchased from 
AAT Bioquest Inc. (Sunnyvale, CA, U.S.A.) and 5-carboxyfluorescein was obtained from Acros Organics 
(Geel, Belgium). Milli-Q plus water (Millipore, Bedford, MA, U.S.A.) was used for all preparations.
Preparation and characterization of GT infusion. The infusion was produced by steeping either 2 
or 4 g of GT in 50 mL of hot deionized water (98–100 °C) for 30 min. The infusion was filtered with gauze 
while hot to afford concentrations of 40 and 80 mg/mL, respectively, which was freshly administered to 
rats via gastric gavage.
For the characterization of GT infusion, after filtration of GT infusion with 0.2 μ m RC15 filter 
(Sartorious, Goettingen Germany), 100 μ L of the filtrate was mixed with 900 μ L of methanol and cen-
trifuged to remove the precipitate. The properly diluted infusion (50 μ L) was combined with 50 μ L of 
6,7-DMC solution (2.0 μ g/mL in methanol) as internal standard, and 5 μ L was subject to LC-MS/MS 
analysis. The HPLC system included Accela 1250 pump and auto-sampler (Thermo Fisher Scientific 
Inc. U.S.A.). Chromatographic separation was achieved using a Phenomenex® C18 analytical column 
(150 mm × 1.0 mm, 5 μ m) with a prefilter. The mobile phase consisted of acetonitrile containing 0.01% 
formic acid (A) and water containing 0.01% formic acid (B) and programmed in a gradient manner as 
follows: A/B: 2/98 (0–2 min), 15/85 (4 min), 40/60 (6 min), 90/10 (8–10 min) and 2/98 (12 min). The 
flow rate was 0.2 mL/min. The column effluent was detected by H-ESI (heated-electrospray ionization) 
-II probe with Quantum Access MAX triple stage quadrupole (TSQ) mass spectrometer (Thermo Fisher 
Scientific Inc. U.S.A.). Nitrogen was used as sheath gas at 35 arbitrary units and auxiliary gas at 10 
arbitrary units. The collision energy was set at − 19/18 V, spray voltage at − 3000/3000 V, capillary tem-
perature at 350 °C, vaporizer temperature at 350 °C and tube lens offset at − 80/88 V. The following mass 
transitions were used for selected reaction monitoring analysis (SRM): EC (289/245), EGC (305/125), 
ECG (441/289), EGCG (457/169), and 6,7-DMC (207/151). The ESI-MS spectra were recorded in nega-
tive ion mode for EC, EGC, ECG and EGCG and positive ion mode for 6,7-DMC.
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Animals. Male Sprague-Dawley rats (270–360 g) were purchased from National Laboratory Animal 
Center (Taipei, Taiwan) and housed in conditioned environment with 12-h light/dark cycles. Food and 
water were acquired ad libitum until 12 h prior to experiments. Rats were divided into two groups. 
The first experiment used 28 rats to determine the effect of GT on the serum levels of IS and PCS 
in CRF rats; the second experiment used 14 rats to evaluate the effect of GT on the renal function 
of CRF rats. All animal experiments were carried out in strict accordance with the recommendations 
by ‘‘The Guidebook for the Care and Use of Laboratory Animals (2002)’’ published by the Chinese 
Society of Animal Science, Taiwan, R.O.C. The experimental protocol had been reviewed and approved 
on 08/01/2014 (Permit Number: 103–126-N) by the Insititutional Animal Care and Use Committee of 
China Medical University, Taiwan, R.O.C.
Establishment of CRF model and administration of GT infusion. CRF was induced via oral 
administration of adenine following previous studies, but with some modification19,23,35,36. Briefly, ade-
nine suspended in 0.5% methylcellulose 400 (15 mg/mL) was orally administered to 28 rats via gastric 
gavage twice daily for seven consecutive doses (15 mg/rat) throughout the experimental period. On day 
4, the serum levels of IS were determined. Upon confirming attenuated renal function by significant 
elevation of serum IS levels, the CRF rats were divided into three groups (8–10 rats in each group) with 
comparable IS levels. The first group received 400 mg/5 mL/kg of GT infusion twice daily for seven con-
secutive doses; the second group received 200 mg/5 mL/kg of GT twice daily for seven consecutive doses; 
and the third group received 5 mL/kg of water in parallel as control. On day 8, rats were administered the 
7th dose of GT at 9:00 am after overnight fast, and the blood samples were collected at 0, 15, 30, 60, 120, 
180 and 360 min after dosing. The scheduled time of blood collection and administrations of adenine and 
GT are summarized in Fig. 3. At each sampling time, 0.5 mL of blood was withdrawn under isoflurane 
anesthesia. The blood samples were collected in microtubes and centrifuged at 10,000 g for 15 min to 
obtain serum, which was stored at − 20 °C before analysis.
Determination of the concentrations of IS and PCS in serum. For the determination of IS and 
PCS concentrations in serum, 50 μ L of serum specimen was vortexed with 200 μ L of methanol containing 
10 μ g/mL of 6,7-DMC or 100 μ g/mL of methylparaben as internal standards, respectively, and centri-
fuged to remove the precipitate, then a 20 μ L aliquot was subject to HPLC analysis.
For calibrator preparations, 50 μ L of serum was spiked with a series of concentrations of IS and PCS 
to afford concentration ranges of 0.4–25.0 μ g/mL (1.8–117.3 μ M) and 0.3–20.0 μ g/mL (1.7–106.3 μ M), 
respectively. The later procedure followed that described above for serum samples. The calibration curves 
were drawn by linear regression of the peak area ratios (IS or PCS to internal standard) against the 
known concentrations of IS and PCS, respectively.
The HPLC apparatus included a pump (LC-10AT, Shimadzu, Kyoto, Japan), fluorescence detector 
(RF-20A, Shimadzu, Kyoto, Japan) and automatic injector (SIL-10AF, Shimadzu, Kyoto, Japan). The 
Apollo C18 (5 μ m, 4.6 mm × 250 mm, Alltech, Deerfield, IL, USA) column was equipped with a guard 
column (4.6 × 50 mm, 5 μ m) (GL Science Inc., Tokyo, Japan). The mobile phase consisted of acetonitrile 
(A)–0.1% phosphoric acid (B) and programmed in a gradient manner as follows: A/B: 15/85 (0–7 min), 
30/70 (9–22 min) and 15/85 (24–35 min) for IS, and 16/84 (0–10 min), 30/70 (13–22 min) and 16/84 
(24–36 min) for PCS. Detector settings were Ex 280 nm/Em 375 nm for IS and Ex 214 nm/Em 306 nm for 
PCS. The flow rates were 1.0 mL/min.
Effect of GT on Cr and BUN in CRF rats. In another experiment, the same animal protocol men-
tioned above was employed, and the concentrations of Cr and BUN were determined before adenine 
treatment (Day 0), before GT dosing (Day 4) and after 7th dose of GT (Day 8). Upon confirming atten-
uated renal function by significant elevation of Cr and BUN on day 4, the CRF rats were divided into 
two groups (7 rats per group) with comparable Cr levels. The first group received 400 mg/5 mL/kg of GT 
twice daily for seven consecutive doses; the second group received 5 mL/kg of water in parallel as control. 
On day 8, rats were administered the 7th dose of GT and water after overnight fast, and the blood samples 
were collected 30 min later. Cr was determined by a kinetic alkaline picrate method in an ADVIA 2400 
Chemistry System (Siemens Health Care Diagnostics, Inc. Tarrytown, NY, U.S.A.). BUN was assayed by 
the urease/glutamate dehydrogenase coupled-enzyme reaction using the same analyser.
Cell line and culture conditions. Construction of the stably transfected cell lines used for transport 
studies, Chinese hamster ovary (CHO) cells expressing hOAT1 (CHO-hOAT1), human embryonic kid-
ney 293 (HEK) cells expressing hOAT3 (HEK-hOAT3) and their corresponding empty vector-transfected 
control cell lines, was described previously40,41. CHO cells were maintained at 37 °C with 5% CO2 in 
DMEM F-12 media (Thermo Fisher Scientific Inc., USA) containing 10% serum, 1% penicillin/strep-
tomycin and 1 mg/mL G418. HEK cells were maintained at 37 °C with 5% CO2 in DMEM high glu-
cose media (Thermo Fisher Scientific Inc., USA) containing 10% serum, 1% penicillin/streptomycin and 
50 μ g/mL hygromycin B. Cells were cultured in Poly-D-Lysine coated dishes.
Preparation and characterization of the serum metabolites of GT (GTM). In order to mimic 
the molecules interacting with OATs in vivo, GTM were prepared from rats and characterized. Briefly, 
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GT infusion (800 mg/10 mL/kg) was orally administered to rats fasted overnight. Blood was collected at 
15 min after dosing of GT infusion. After coagulation, the serum was collected and vortexed with 3-fold 
methanol. Following centrifugation at 10,000 g for 15 min, the supernatant was concentrated in a rotatory 
evaporator under vacuum to dryness. An appropriate volume of water was added to the residue yielding 
a solution with 10-fold serum concentration, which was divided into aliquots and stored at − 80 °C for 
later use.
A portion of GTM was characterized following a previous method with some modifications16,46. 
Briefly, 100 μ L of serum sample was mixed with 50 μ L of sulfatase (containing 1000 units/mL of sulfatase 
and 39,861 units/ml of ß-glucuronidase), 50 μ L of ascorbic acid (200 mg/mL) and incubated at 37 °C for 
45 min under anaerobic condition. After hydrolysis, the serum was added to 50 μ L 0.1 N HCl and then 
partitioned with 250 μ L of ethyl acetate (containing 100 ng/mL of 6,7-DMC as internal standard). The 
ethyl acetate layer was evaporated under N2 to dryness and reconstituted with an appropriate volume 
of mobile phase prior to LC-MS/MS analysis. The mobile phase consisted of acetonitrile (A) – water 
containing 0.1% formic acid (B) and programmed in a gradient manner as follows: A/B: 2/98 (0–2 min), 
15/85 (4 min), 40/60 (6 min), 90/10 (8–10 min) and 2/98 (12 min). The flow rate was 0.2 mL/min.
Effects of GTM on the uptake transport mediated by hOAT1 and hOAT3. CHO-hOAT1 and 
HEK-hOAT3 cells (1 × 105 cells/well) were cultured in a 96-well plate. 6-Carboxyfluorescein (6-CF) and 
5-carboxyfluorescein (5-CF) were used as probes for evaluating the effect of GTM on the activity of 
hOAT1 and hOAT3, respectively47,48. In addition, probenecid (80 μ M) was used as a positive control 
for inhibition of hOAT1 and hOAT349. After 24 h or 48 h incubation of CHO-hOAT1 or HEK-hOAT3, 
the medium was removed and washed three times with PBS buffer. Before the transport experiment, 
CHO-hOAT1 and HEK-hOAT3 cells were pre-incubated with test agents (GTM and probenecid) at 
37 °C. After 30 min incubation, 6-CF or 5-CF was then added and incubated for another 5 min and 
10 min, respectively. The plates were immediately placed on ice bath, and the supernatants were removed 
and the cells were washed three times with ice-cold PBS. Subsequently, 100 μ L of 0.1% Triton X-100 
was added to lyse the cells and the fluorescence was measured with excitation at 485 nm and emission 
at 528 nm. To quantitate the content of protein in each well, 10 μ L of cell lysate was added to 200 μ L of 
diluted protein assay reagent (Bio-Rad, Hercules, CA, U.S.A.) and the optical density was measured at 
570 nm. The relative intracellular accumulation of 6-CF or 5-CF was calculated by comparing with that 
of controls after protein correction.
Data analysis. The peak serum concentration (Cmax) was obtained from experimental observation. 
The area under the serum concentration - time curve (AUC0-t) was calculated using trapezoidal rule 
to the last point. The differences of IS and PCS among three groups were analyzed by using one-way 
ANOVA, while the difference of Cr and BUN between two groups was analyzed by using unpaired 
Student’s t-test, taking p < 0.05 as significant level. Unpaired Student’s t-test was also used for the analysis 
of in vitro assays.
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